All LLY Content

Eli Lilly and Company (LLY) Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 19, 20261 min read

Eli Lilly and Company (LLY) Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 16, 20261 min read

Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript

Eli Lilly and Company (NYSE: LLY) Q4 2025 Earnings Call dated Feb. 04, 2026 Corporate Participants: Mike Czapar — Director...

March 10, 202650 min read

Eli Lilly and Company (LLY) Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 5, 20261 min read

Eli Lilly and Company (LLY) Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 3, 20261 min read

Eli Lilly and Company (LLY) Lilly’s Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

February 27, 20261 min read

Eli Lilly and Company (LLY) Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

February 26, 20261 min read

Breaking News

Eli Lilly and Company (LLY) Surges 5.1% — Developing Story

Eli Lilly and Company (LLY) Surges 5.1% — Developing Story

February 23, 20261 min read

Eli Lilly and Company (LLY) Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

February 23, 20261 min read

Eli Lilly and Company (LLY) Patients with Crohn’s disease maintained steroid-free remission for three years with Lilly’s Omvoh (mirikizumab-mrkz)

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

February 19, 20261 min read